About Us

Advancing Precision Genetic Therapies With the Potential to Restore, Improve and Preserve Hearing

Listening is in our DNA.

Ακούω in Greek translates to Listen in English. At Akouos (ah KOO ohs), we strive to be a team that listens to one another, to healthcare providers, and to the deaf and hard of hearing (D/HH) community. Our partnerships and collaborations are focused on common goals and predicated on respect, trust, and transparency.

Common Goal Partnerships

In partnering with the D/HH community, we will use the principles outlined here as our guide.

Hearing loss is one of the greatest challenges in medicine today, and with no FDA-approved pharmacologic therapies available, an area of severe unmet need.

Manny Simons, PH.Dfounder and CEO of Akouos

We Are Akouos

  • Filter By:

  • John Connelly

    SENIOR VICE PRESIDENT, PORTFOLIO STRATEGY & R&D OPERATIONS

  • Aninda Katragadda

    FINANCE CONSULTANT

  • Michael McKenna

    CHIEF MEDICAL OFFICER & CO-FOUNDER

  • Sachiyo Minegishi

    CHIEF FINANCIAL OFFICER

  • Morgan Molloy

    CHIEF CORPORATE DEVELOPMENT OFFICER

  • Rabia Gurses Ozden

    CHIEF DEVELOPMENT OFFICER

  • Greg Robinson

    CHIEF SCIENTIFIC OFFICER

  • Karoline Shair

    CHIEF LEGAL OFFICER & CORPORATE SECRETARY

  • Emmanuel Simons

    PRESIDENT & CO-FOUNDER

  • Alan Smith

    CHIEF TECHNOLOGY OFFICER

  • Jennifer Wellman

    CHIEF OPERATING OFFICER

Our Partners

Join us in the pursuit of healthy hearing for all.

What’s at our core

We Work to Change Lives

Akouos listens: to each other, to the individuals and families we work to serve, to our collective conscience.
Akouos engages: Honestly, transparently, respectfully.
Akouos leads: Authentically, boldly, bravely, with purpose and passion.
Akouos creates: High standards, opportunities to excel, better medicines.
Akouos trusts: Ourselves, each other, our science.

Join us in the pursuit of healthy hearing for all.

Akouos is building a leading gene therapy company focused on hearing disorders. Our objectives are to restore the inner ear’s ability to produce functional proteins required for hearing, rejuvenate structures of the hearing circuit critical for high-fidelity signal transduction and inner ear homeostasis, and reinforce healthy hearing with local, enduring protein production to protect against drug-, noise-, and age- associated ototoxicity.